



**15 to 18
November
2023**



**15 to 18
November
2023**



**15 to 18
November
2023**



Thursday, November 16, 2023				
9:00 - 11:00	Plenary 1 - Global Experience in Progress to Cervical Cancer Elimination Asia, Africa, North America, South America, Europe			
11:00 - 11:30	Coffee Break			
11:30 - 13:00	Vaccination & Screening	Screening strategies	Clinical Challenges	Free Communications.
11:30 - 11:50	Impact of HPV vaccines on cervical cancer incidence: perspectives	Self sampling HPV Testing: implementation Challenges in LMIC	AGC: what to do next?	
11:50 - 12:10	HPV Faster protocol: is this the way?	Reflex Cytology as a triage test: clinical performance	Colposcopy challenges: Glandular Lesions	
12:10 - 12:30	HPV vaccines for Head and Neck cancer prevention. Do we have screening?	HPV genotyping as a triage test	Methods of Endocervical sampling: value and indications	
12:30 - 12:50	HPV vaccines for Anal cancer prevention	Dual Immunostaining triage	AIS treatment and follow-up: what's new?	
11:50 - 13:00	Q&A	Q&A	Q&A	
13:00 - 14:00	Sponsored Symposia	Sponsored Symposia	Sponsored Symposia	Sponsored Symposia
14:30 - 15:30	Plenary 2 - New Screening methods Across the World			
14:30 - 14:50	WHO algorithms of screening			
14:50 - 15:10	Risk based Screening: ASCCP			
15:10 - 15:30	Screening in vaccinated population			
15:30 - 16:00	Coffee Break			
16:00 - 17:30	Vaccination & Screening Experiences During COVID 19 Pandemic	New Developments in HPV Diagnostics	Clinical Challenges	Clinical Cases
16:00 - 16:25	Update in Global Vaccination Coverage and Covid-19 impact	Molecular triage of HPV positive women (E6 & E7 prot)	Conservative Management of CIN 2	
16:25 - 16:50	Pandemic impact on cervical screening	New HPV Test - True NAAT	Colposcopic challenge: Microinvasion	
16:50 - 17:15	Post pandemic strategies to improve screening and vaccination	Methylation as triage tool for cervical cancer	Colposcopic Challenges: ZT type 3	
17:15 - 17:30	Q&A	Q&A	Q&A	

Friday, November 17, 2023				
9:00 - 11:00	Plenary - Microbiome			
9:00 - 9:25	Microbiome modifications during life			
9:25 - 9:50	Microbiome in women with HSIL			
9:50 - 10:15	Can we Treat Microbiome			
10:15 - 10:45	HPV infection: implication of nutraceuticals and microbiome			
11:00 - 11:30	Coffee Break			
11:30 - 13:00	Vaccination	Screening and biomarkers	Nomenclature Session	HPV related disease in special population
11:30 - 11:50	HPV Vaccine: impact in males	Prognostic biomarkers for progression of HSIL	IFCPC 2011 Colposcopy Nomenclature (Pros)	HPV and HIV
11:50 - 12:10	Transmissibility and elimination: concept of even faster	Wich test can be used for clinical efficacy (validation)	IFCPC 2011 Colposcopy Nomenclature (cons) (to vote)	Screening in transgender population
12:10 - 12:30	HPV Vaccination and Social Media: a real world challenge	Is there still a role of PAP smear in primary screening?	VIN and Vulvar cancer Terminology	Screening & Vaccination in immunocompromised
12:30 - 12:50	Single dose HPV vaccine: long term efficacy	What is the relevance of HPV persistence?	FIGO 2021 Cervical cancer classification	Treatment failure in immunocompromised
12:50 - 13:00	Q&A	Q&A	Q&A	Q&A
13:00 - 14:00	Sponsored Symposia	Sponsored Symposia	Sponsored Symposia	Sponsored Symposia
9:00 - 11:00	Plenary - HPV Vaccination experiences across the world			
14:30 - 14:50	Australia: toward the elimination of cervical cancer by 2030			
14:50 - 15:10	Argentina: neutral gender national program			
15:10 - 15:30	Colombia: the impact of negative media campaign in the national program			
15:30 - 16:00	Coffee Break			
16:00 - 17:30	Women treated for CIN:	Impact of HPV Diagnosis	Clinical colposcopic challenges	Vaginal Disease. EFC session
16:00 - 16:25	Post Treatment HPV Vaccination	What kind of information you give to HPV positive patient	Colposcopy in pregnancy	Vaginal premalignant lesion: diagnosis
16:25 - 16:50	Test of cure: follow-up strategies	Psychological and Sexual impact of HPV diagnosis	Who should be referred for HRA (high-resolution anoscopy)?	Vaginal lesions: treatment options
16:50 - 17:15	Re-infection and re-activation: key points	Quality of life changes in HPV positive	Cervical cancer HPV negative cases	Mutizonal disease
17:15 - 17:30	Q&A	Q&A	Q&A	

Saturday, November 18, 2023				
9:00 - 11:00	Plenary - Colposcopy quality assurance			
9:00 - 9:25	Quality assurance overview			
9:25 - 9:50	BSCCP: European standars in colposcopy			
9:50 - 10:15	Standard in colposcopy in America			
10:15 - 10:45	Standard in colposcopy in Asia			
11:00 - 11:30	Coffee Break			
11:30 - 13:00	Screen & Treat	Vulvar & Disease (skip)	Colposcopic images	Artificial Intelligence (AI) in cervical pathology
11:30 - 11:50	Clinical scenarios for screen & treat strategy	WHO 2020 VIN classification	ESTAMPA protocol: results of colposcopy performance in HPV infected women	Artificial Intelligence (AI) in colposcopy: implementation Challenges
11:50 - 12:10	ESTAMPA protocol: preliminary results of VIA performance	Diagnosis and treatment of dVIN	Colposcopic images in H-SIL lesions	Transvaginal device with AI
12:10 - 12:30	Performance of thermal ablation	Diagnosis and treatment of Lichen Sclerosus	Colpo-cito-histologic images correlation in HPV related lesions	AI new devices: DySIS - Zedscan Urine and HPV Testing.
12:30 - 12:50	The future of Screen & Treat	Genital Warts: is this a risk indicator?	EVA System	
12:50 - 13:00	Q&A	Q&A	Q&A	Q&A
13:00 - 14:00	CLOSING CEREMONY			